Repros Names Larry Dillaha, M.D., its Permanent President and CEO
April 10, 2017 09:18 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, April 10, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the Company’s Board of Directors has appointed Larry Dillaha, M.D., the...
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids
April 10, 2017 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, April 10, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the Company held a meeting with the FDA to discuss the progress and next steps...
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
March 31, 2017 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, March 31, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2016. Financial...
Repros Announces New CEO
February 02, 2017 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski is leaving his position as President and Chief Executive...
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids
January 30, 2017 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has granted an “end of Phase 2” meeting to discuss the Phase 3 requirements to...
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis
December 19, 2016 16:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has requested a meeting to discuss Phase 3 requirements for the development of...
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids
December 12, 2016 16:01 ET
|
Repros Therapeutics Inc.
Focus on oral formulationPhase II complete THE WOODLANDS, Texas, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has requested a meeting to discuss...
FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
December 06, 2016 20:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) participated in the industry presentation at the Bone, Reproductive and Urologic Drugs Advisory...
Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids
November 14, 2016 16:01 ET
|
Repros Therapeutics Inc.
Primary endpoint of induction of amenorrhea met for both pooled oral and vaginal delivery compared to placebo, p<0.0001 and p=0.0071, respectivelyStatistically significant reduction in fibroid size...
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
November 08, 2016 16:00 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2016. Financial Results...